Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

Authors:

Abstract
Daratumumab is approved as monotherapy and in combination regimens for the treatment of relapsed or refractory multiple myeloma (RRMM) or newly diagnosed multiple myeloma [1,2]. The PAVO study (Cli...
Funding Information
  • Janssen Research & Development, LLC (NCT02519452)

This publication has 13 references indexed in Scilit: